<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48286">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02477605</url>
  </required_header>
  <id_info>
    <org_study_id>VRH172-P001</org_study_id>
    <nct_id>NCT02477605</nct_id>
  </id_info>
  <brief_title>Clinical Comparison of 27+® and 23-gauge ULTRAVIT® 7500 Cpm Vitrectomy Outcomes</brief_title>
  <official_title>Clinical Comparison of 27+® and 23-gauge ULTRAVIT® 7500 Cpm Vitrectomy Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the treatment day change between immediate
      postoperative and immediate preoperative intraocular pressure (IOP) between 27-gauge and
      23-gauge vitrectomy instruments.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Required follow-up for this study is 3 months post treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in IOP on Operative Day</measure>
    <time_frame>Day 0 preoperative, Day 0 postoperative</time_frame>
    <description>IOP (fluid pressure inside the eye) will be assessed using the study specified tono-pen and is measured in millimeters of mercury (mmHg). Change is defined as the difference between immediate postoperative IOP and immediate preoperative IOP. A greater change in IOP may indicate a less stable posterior chamber and/or a more invasive surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Conjunctival Edema Score at Week 1</measure>
    <time_frame>Week 1 post operative</time_frame>
    <description>Conjunctival edema (swelling) will be assessed during examination by the investigator and graded using a score of 0-3, where 0=Absent and 3=Severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Post-operative Pain Rating at Day 1</measure>
    <time_frame>Day 1 post operative</time_frame>
    <description>The subject will be asked to rate post-operative pain in the study eye using a score of 0-10, where 0=no pain and 10=the worst pain imaginable.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">137</enrollment>
  <condition>Vitreoretinal Disease</condition>
  <arm_group>
    <arm_group_label>27-gauge pak</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CONSTELLATION 27-gauge combined surgical pak used during vitrectomy surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>23-gauge pak</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CONSTELLATION 23-gauge combined surgical pak used during vitrectomy surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CONSTELLATION 27-gauge Combined Surgical Pak</intervention_name>
    <description>Sterile single-use supplies necessary to perform 1 vitrectomy surgery: 1 ULTRAVIT® 27-gauge 7500 cuts per minute (cpm) vitrectomy probe and a 27-gauge EDGEPLUS Valved Entry System comprised of 3 trocar/cannulas and related accessories.</description>
    <arm_group_label>27-gauge pak</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CONSTELLATION 23-gauge Combined Surgical Pak</intervention_name>
    <description>Sterile single-use supplies necessary to perform 1 vitrectomy surgery: 1 ULTRAVIT® 23-gauge 7500 cuts per minute (cpm) vitrectomy probe and a 23-gauge EDGEPLUS trocar/cannula set comprising of 3 trocars/cannulas and related accessories.</description>
    <arm_group_label>23-gauge pak</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Vitrectomy surgery</intervention_name>
    <description>Microincisional pars plana vitrectomy (PPV) surgery for the treatment of various vitreoretinal diseases ranging from simple to advanced cases</description>
    <arm_group_label>27-gauge pak</arm_group_label>
    <arm_group_label>23-gauge pak</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to provide informed consent and attend all required study visits;

          -  Requires vitrectomy in at least one eye;

          -  Other protocol-defined inclusion criteria may apply.

        Exclusion Criteria:

          -  Previous vitrectomy or glaucoma surgery;

          -  Planned treatment requires scleral buckling, combined procedures (eg, cataract
             surgery), silicone oil, and expansive gas other than sterile air;

          -  Treated with topical IOP lowering medication(s) at any time from baseline assessment
             to time of surgery;

          -  Pregnant or planning to become pregnant during the course of the trial;

          -  Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Senior Clinical Manager, Surgical, GCRA</last_name>
    <role>Study Director</role>
    <affiliation>Alcon, A Novartis Division</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Contact Alcon Call Center for Trial Locations</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>February 27, 2017</lastchanged_date>
  <firstreceived_date>June 18, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
